Xbrane Biopharma AB is a leading science based biosimilar developer of cost effective medicines with high unmet medical need. Xbrane base its development on a patented high yield production platform and world-leading expertise. Xbrane has a portfolio targeting originator products with combined annual sales of €11billion. The leading product, Xlucane (ranibizumab biosimilar), is currently in Phase III with target to launch 2022. Xbrane’s headquarter is located in Solna, just outside of Stockholm. Xbrane is listed on Nasdaq Stockholm with the ticker XBRANE.
Location: Sweden, Stockholm
Member count: 51-200
Founded date: 2008
Investors 1
| Date | Name | Website |
| - | Beijer Ven... | beijervent... |
Mentions in press and media 7
| Date | Title | Description | Category | Author | Source |
| 01.07.2021 | Xbrane Bio... | NOT FOR RELEASE, PUBLICATION O... | - | - | marketscre... |
| 28.06.2021 | Xbrane Bio... | Xbrane Biopharma AB (publ) ('X... | - | - | marketscre... |
| 13.11.2020 | XBRANE BIO... | Interim report January - Septe... | - | - | marketscre... |
| 13.11.2020 | Xbrane Bio... | Interim report January - Septe... | - | - | marketscre... |
| 12.11.2020 | XBRANE BIO... | The board of directors of the ... | - | - | marketscre... |
| 12.11.2020 | Xbrane Bio... | The board of directors of the ... | - | - | marketscre... |
| 15.10.2015 | Xbrane Acq... | Xbrane, a Stockholm, Sweden-ba... | Italy Swe... | - | finsmes.co... |